LEIDOS BIOMEDICAL RESEARCH INC: $485M Department of Health and Human Services Contract
Summary
Leidos Holdings ($LDOS) received a $485M task order from NIH's National Cancer Institute for operational support through FY27. This represents ~1.6% of annual revenue, providing stable backlog growth for Leidos's health segment.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Leidos wins $485M NIH task order for cancer research support, adding ~1.6% to annual revenue.
- 2.Contract runs FY26-FY27, providing multi-year revenue stability.
- 3.No direct legislative connection; award is a routine operational renewal.
Market Implications
For Leidos Holdings, this contract provides a modest but reliable revenue stream in its health segment. Investors should view this as a positive signal of continued government demand for biomedical research support services. The stock may see incremental gains as backlog grows, but the impact is limited given Leidos's size. No major sector-wide implications are expected.
Full Analysis
The Department of Health and Human Services, through the National Institutes of Health, awarded a $485M delivery order to Leidos Biomedical Research Inc for NCI operational task orders covering FY26-FY27. Leidos Biomedical Research is a wholly owned subsidiary of Leidos Holdings, a publicly traded technology and defense contractor. This contract is a renewal of existing support services for cancer research operations, indicating sustained government investment in biomedical research infrastructure.
For Leidos Holdings, with FY2025 revenue of $15.3B, this contract adds approximately $242.5M per year, or 1.6% of total revenue. While not transformative, it provides predictable cash flow and reinforces Leidos's relationship with NIH. Leidos's health segment, which includes biomedical research and health IT, benefits directly. The company's net margin of 1.3% in FY2025 suggests that even modest revenue additions can contribute to profitability.
No specific legislation is directly tied to this award among the provided bill signals. The contract appears to be a routine task order under existing appropriations for NIH operations. However, the broader trend of federal investment in health research supports continued demand for such services.
Potential subcontractors or supply chain beneficiaries could include smaller healthcare IT firms or research support companies, though specific names are not disclosed. Companies like IQVIA ($IQV) or Veeva Systems ($VEEV) operate in adjacent spaces but are not directly linked.
Historically, Leidos has consistently won large government task orders, and such awards typically lead to stable revenue recognition over the contract period. The stock may see modest positive sentiment as the award reinforces backlog and earnings visibility.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
LEIDOS BIOMEDICAL RESEARCH INC: $372M Department of Health and Human Services Contract
LEIDOS, INC.: $18.8M Department of Homeland Security Contract
LEIDOS, INC.: $39.7M Department of Homeland Security Contract
LEIDOS, INC.: $192M General Services Administration Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Declaring a National Emergency to Secure the United States Bulk-Power System
This executive order declares a national emergency to restrict foreign-produced bulk-power system electric equipment that poses national security risks, prohibiting new transactions involving equipment from covered foreign entities and allowing the Secretary of Energy to impose conditions on existing equipment. It directs the Secretary of Energy, in coordination with multiple agencies, to identify, mitigate, and potentially replace risky equipment, and establishes a pre-qualification list for approved vendors.
The National Space Transportation Policy
This memorandum directs multiple agencies to expand and modernize U.S. space launch and reentry infrastructure to support over 1,000 launches annually by 2030, expedite permitting and environmental reviews, develop new federal reentry sites, and strengthen the space transportation industrial base. It mandates range scheduling transparency, spectrum reliability, and workforce development, with specific reports and plans due within 90 to 240 days.
Adjusting Imports of Unmanned Aircraft Systems and Unmanned Aircraft Systems Components into the United States
This proclamation imposes a 100% ad valorem tariff on imports of unmanned aircraft systems (UAS) over 25 kg, those with thermal imagers, docking stations, and certain components, and a 25% tariff on UAS under 25 kg and other components, citing national security under Section 232 of the Trade Expansion Act. It also authorizes the Department of Commerce to establish an onshoring program offering preferential tariff treatment for companies that build new U.S. manufacturing facilities for UAS and components.
Contract Details
Recipient
LEIDOS BIOMEDICAL RESEARCH INC
Award Amount
$485,491,548
Awarding Agency
Department of Health and Human Services
Sub-Agency
National Institutes of Health
Contract Type
DELIVERY ORDER
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →